跳至主要内容
临床试验/NCT01811524
NCT01811524已完成不适用

The Etiology and Progression of Brain Tumors - Molecular Genetic Changes and Heredity

Tampere University Hospital0 个研究点目标入组 2,000 人开始时间: 2013年3月14日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
2,000
主要终点
The prognostic value of new biomarkers in brain tumors

研究概览

简要总结

The main goal of the study is to present a framework, which integrates DNA, RNA and tissue data to identify and prioritize genetic events that represent clinically relevant new therapeutic targets and prognostic biomarkers for different kinds of brain tumors. The investigators study the regulation of neoplastic cell growth by oncogenes, tumor-suppressor and other cancer related genes using modern molecular genetic methods, such as chromogenic-in-situ hybridization, comparative genomic hybridization (CGH), array-CGH, cDNA microarray etc. In these studies the investigators utilize disease-specific tissue microarrays (TMA) which the investigators have constructed since 1999. Until now up to 3000 different brain tumours have been sampled to our TMA:s. These permit high-volume simultaneous analysis of molecular targets at the DNA, mRNA and protein levels. Research group has also focused its interest on the neoplastic development of gliomas, particularly on their hereditary and environmental factors.

详细描述

Aims of the study:

  1. To collect adequate brain cancer tissue material for high throughput morphological, protein, RNA and DNA analyses.
  2. To combine tissue-related results of these analyses with clinical data to examine the potential of the new biomarkers to assess diagnosis, prognosis and heredity of brain tumors.

Materials and Methods

Paraffin-embedded tumor material

Paraffin blocks of more than 4,000 brain tumours have been collected into the Laboratory of Pathology at Tampere University Hospital (Department of Pathology in Fimlab Laboratory). They have been used primarily for purposes of clinical diagnosis, but once patient or authority consent has been obtained the surplus of the material can be used for research purposes. A neuropathologist has marked the most representative region of each tumour in a tissue slide. Using these markings, tumour tissue regions are then biopsied into the tissue microarray block (Micro-Array Technology, Beecher Instruments, Inc.). Up to 1,000 histological samples can be collected into one tissue microarray block, which can be cut into 200 tissue sections. These sections can be used in various kinds of analysis (immunohistochemistry, fluorescence and chromogene in situ hybridisation and other histological standings). Among the advantages of the method are its high capacity, potential for automation, limited damage to the original tissue block and optimised circumstances for molecular biological analyses. We produced the first Finnish TMA block in 1999. Until now up to 3000 different brain tumors have been sampled to our TMA:s of which 2000 gliomas and meningiomas are used for this study. The following provides examples of projects in which the method is used. Similar strategies are used in the present study:

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
1 Month 至 85 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • all glioma and meningioma patients 1983 - 2009

排除标准

  • 未提供

结局指标

主要结局

The prognostic value of new biomarkers in brain tumors

时间窗: September 1983 - December 2009

次要结局

  • Heredity of brain tumors(September 1983 - December 2000)

研究者

申办方类型
Other
责任方
Sponsor

相似试验